China SXT Pharmaceuticals, Inc. (SXTC) Gross profit 2017–2026
China SXT Pharmaceuticals, Inc. (SXTC) annual gross profit history from SEC filings — each fiscal year as reported.
$248,702FY2026 · since FY2017: $2.3M → $248,702
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | $248,702 | -32.3% |
| FY2025 | $367,427 | -33.7% |
| FY2024 | $553,971 | +30.0% |
| FY2023 | $426,271 | -65.9% |
| FY2022 | $1.3M | -55.9% |
| FY2021 | $2.8M | +5.0% |
| FY2020 | $2.7M | -41.4% |
| FY2019 | $4.6M | +35.6% |
| FY2018 | $3.4M | +47.1% |
| FY2017 | $2.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More SXTC financial trends
SXTC RevenueSXTC Net incomeSXTC Net marginSXTC Gross marginSXTC Operating incomeSXTC Operating marginSXTC Operating cash flowSXTC Free cash flowSXTC Capital expendituresSXTC Return on equitySXTC Stock buybacksSXTC Dividends paidSXTC Total assetsSXTC Total liabilitiesSXTC Shareholders’ equitySXTC overview →